异丙托溴铵联合布地奈德治疗重度气流受限老年慢性阻塞性肺疾病的临床观察
|
摘要
目的观察异丙托溴铵联合布地奈德吸入治疗重度气流受限的老年慢性阻塞性肺疾病(COPD)的疗效与安全性。方法 62例重度气流受限老年COPD患者随机分为对照组和实验组,分别给予异丙托溴铵气雾剂、异丙托溴铵气雾剂联合布地奈德吸入剂治疗6个月。观察两组的疗效与安全性。结果两组治疗后第一秒用力呼气量(FEV1)、用力肺活量、FEV1占预计值百分比值均较治疗前升高,且以实验组更为显著(P<0.01)。两组总有效率及不良反应总发生率差异均无统计学意义(P>0.05)。结论异丙托溴铵联合布地奈德吸入治疗重度气流受限老年COPD对肺功能改善效果优于单独使用异丙托溴铵。
Objective To observe the efficacy and safety of ipratropium bromide and budesonide inhalation in elderly COPD patients with severe airflow limitation. Methods Sixty-two elderly COPD patients with severe airflow limitation were randomly treated with ipratropium bromide aerosol(control group) or ipratropium bromide aerosol and budesonide inhalation(experimental group). The clinical effect and safety were compared between 2 groups. Results The forced expiratory volume in 1 second(FEV1), forced vital capacity(FVC), and FEV1% pred were increased after treatment in 2 groups, especially in experimental group(P<0.01). The total effective rate and incidence of adverse reactions were comparable between 2 groups(P>0.05). Conclusion Combined application of ipratropium bromide and budesonide inhalation is superior to single use of ipratropium bromide for improving the lung function in elderly COPD patients with severe airflow limitation.
Objective To observe the efficacy and safety of ipratropium bromide and budesonide inhalation in elderly COPD patients with severe airflow limitation. Methods Sixty-two elderly COPD patients with severe airflow limitation were randomly treated with ipratropium bromide aerosol(control group) or ipratropium bromide aerosol and budesonide inhalation(experimental group). The clinical effect and safety were compared between 2 groups. Results The forced expiratory volume in 1 second(FEV1), forced vital capacity(FVC), and FEV1% pred were increased after treatment in 2 groups, especially in experimental group(P<0.01). The total effective rate and incidence of adverse reactions were comparable between 2 groups(P>0.05). Conclusion Combined application of ipratropium bromide and budesonide inhalation is superior to single use of ipratropium bromide for improving the lung function in elderly COPD patients with severe airflow limitation.
引文
[1]中华医学会呼吸病学分会慢性阻塞性肺疾病学组.慢性阻塞性肺疾病诊治指南(2013年修订)[J].中华结核和呼吸杂志,2013,36(4):1-10.
[2]范继秀.布地奈德联合孟鲁司特对老年慢性阻塞性肺疾病急性加重期的影响[J].中国药物与临床,2018,18(S1):44-46.
[3]公维涛,孙杰,郭永忠.布地奈德福莫特罗单药与联合噻托溴铵治疗D组COPD对患者肺功能及生活质量的影响比较[J].贵州医药,2018,42(7):812-813.
[4]郭林霞.布地奈德联合沙丁胺醇雾化吸入对慢性阻塞性肺疾病患者动脉血气指标改善及肺功能的影响[J].慢性病学杂志,2018,19(7):888-889,892.
[5]李星洪,吴卓荣,陈树英,等.布地奈德联合特布他林雾化吸入治疗COPD疗效及对CRP、肺功能的影响[J].江西医药,2018,53(6):579-581.
[6]李明.探讨分析雾化吸入沙丁胺醇、布地奈德与异丙托溴铵治疗老年支气管哮喘急性发作期的临床效果[J].名医,2018(2):13-16.
[7]韩莎莎.布地奈德与异丙托溴铵联合雾化吸入治疗老年阻塞性肺气肿临床效果[J].中国现代药物应用,2018,12(21):66-68.
[8]JIANG D H,WANG X,LIU L S,et al.The effect of ventilator mask atomization inhalation of ipratropium bromide and budesonide suspension liquid in the treatment of COPD in acute exacerbation period on circulating levels of inflammation and prognosis[J].Eur Rev Med Pharmaco Sci,2017,21(22):5211-5216.
[9]肖林,卢丹,陈文荣,等.吸入布地奈德治疗支气管扩张伴喘息的临床观察[J].广东医学院学报,2012,30(3):258-260,263.
[10]LU S,PAREKH D D,KUZNETSOVA O,et al.An oral selective M3 cholinergic receptor antagonist in COPD[J].Eur Respir J,2006,28(4):772-780.
[11]YUKSEL H,COSKUN S,POLATt M,et al.Lower arrythmogenic risk of low dose albuterol plus ipratropium[J].Indian J Pediatr,2001,68(10):945-949.
[2]范继秀.布地奈德联合孟鲁司特对老年慢性阻塞性肺疾病急性加重期的影响[J].中国药物与临床,2018,18(S1):44-46.
[3]公维涛,孙杰,郭永忠.布地奈德福莫特罗单药与联合噻托溴铵治疗D组COPD对患者肺功能及生活质量的影响比较[J].贵州医药,2018,42(7):812-813.
[4]郭林霞.布地奈德联合沙丁胺醇雾化吸入对慢性阻塞性肺疾病患者动脉血气指标改善及肺功能的影响[J].慢性病学杂志,2018,19(7):888-889,892.
[5]李星洪,吴卓荣,陈树英,等.布地奈德联合特布他林雾化吸入治疗COPD疗效及对CRP、肺功能的影响[J].江西医药,2018,53(6):579-581.
[6]李明.探讨分析雾化吸入沙丁胺醇、布地奈德与异丙托溴铵治疗老年支气管哮喘急性发作期的临床效果[J].名医,2018(2):13-16.
[7]韩莎莎.布地奈德与异丙托溴铵联合雾化吸入治疗老年阻塞性肺气肿临床效果[J].中国现代药物应用,2018,12(21):66-68.
[8]JIANG D H,WANG X,LIU L S,et al.The effect of ventilator mask atomization inhalation of ipratropium bromide and budesonide suspension liquid in the treatment of COPD in acute exacerbation period on circulating levels of inflammation and prognosis[J].Eur Rev Med Pharmaco Sci,2017,21(22):5211-5216.
[9]肖林,卢丹,陈文荣,等.吸入布地奈德治疗支气管扩张伴喘息的临床观察[J].广东医学院学报,2012,30(3):258-260,263.
[10]LU S,PAREKH D D,KUZNETSOVA O,et al.An oral selective M3 cholinergic receptor antagonist in COPD[J].Eur Respir J,2006,28(4):772-780.
[11]YUKSEL H,COSKUN S,POLATt M,et al.Lower arrythmogenic risk of low dose albuterol plus ipratropium[J].Indian J Pediatr,2001,68(10):945-949.